AstraZeneca’s Farxiga gets FDA priority review for heart failure with HFrEF

This article was originally published here

As per the supplemental New Drug Application (sNDA), AstraZeneca is seeking approval for Farxiga for its use in lowering the risk of cardiovascular (CV) death or the worsening

The post AstraZeneca’s Farxiga gets FDA priority review for heart failure with HFrEF appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply